Novel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer (MS SPOC)

Originally presented July 25, 2018 as part of the UNC Cancer Network Medical and Surgical Oncology Lecture Series. This Self-Paced, Online Course expired August 28, 2019.

This is a Non-Credit course and does NOT offer continuing education credits.

Presenter

Michael Lee, MD
Assistant Professor
Molecular Therapeutics
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Novel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer

Treatment of metastatic colorectal cancer has continued to evolve over the last several years, with emerging identification of biomarkers that underlie heterogeneity of responses to new and existing therapy. Ongoing clinical research seeks to identify new therapeutic options in molecularly-defined subgroups of patients. We will review the most exciting and clinically impactful research findings in this presentation.

Learning Outcomes

  • Discuss important clinicopathologic features underlying the biology of colorectal cancer
  • Describe varying sequences of therapies in management of metastatic colorectal cancer
  • Describe biomarkers that guide selection and personalization of therapies for patients with advanced colorectal cancer

Credits Offered

  • 1.0 ANCC (CNE) hours of study.
  • 1 ASRT Category A CE Credit
  • 1.0 AMA PRA Category 1 Credit
  • General Participation

Requirements

To receive credit for this course, you must:

  1. Watch a lecture video recording.
  2. Complete the lecture post test and obtain a passing score of 80% or higher.
  3. Complete the course evaluation.
  4. Select credit type.

Estimated course completion time: 1 hour

Disclosures

This activity has been planned and implemented under the sole supervision of the course directors, in association with the UNC Office of Continuing Professional Development (UNC CPD). Dr. Thomas Shea consults for Spectrum Pharma and receives research support from Millennium, Otsuka, GSK, BMS, Novartis and Seattle Genetics. Dr. James Coghill, MD, and CPD staff have no relevant financial relationships with commercial interests as defined by the ACCME.

The speaker, Michael Lee, MD, has no conflict of interest relevant to this presentation.

Accreditation

This is a Non-Credit course and does NOT offer continuing education credits.

Disclaimer

Please note: This course was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. Questions about personal health should always be referred to a physician or other health care professional.